Ovarian cancer account for the greatest numbers of mortality from the malignancies of female genital tract and it is one of the leading cause of cancer fatalities in women. Ovarian cancer is a heterogeneous disease and tumors can be categorized based on cells of its origin. Among ovarian cancers, surface epithelial tumors accounts for approximately 2/3rd
of all ovarian neoplasm and their malignant forms represent about 90% of ovarian cancers in western world. CA125 is gold standard tumor marker for ovarian cancer and its serum level is used to monitor response to chemotherapy, disease progression and recurrence. So, it is reasonable to investigate whether CA125 has utility as prognostic indicator. In this study we observe ovarian cancer patient for two years (Jan 2018- Dec 2019).
Material and methods: This study was carried out at Chittaranjan National Cancer Institute, Kolkata on 50 histologically diagnosed cases whose serum CA125 levels have been estimated. Considering the stage, the patients were divided in two groups. Group I consisting early stage Ovarian Carcinoma (FIGO Classification I), while group II included advanced disease Ovarian Carcinoma (FIGO Classification II, III & IV). We studied an association between preoperative serum CA125 and known prognostic factors of Ovarian Cancer (stage and recurrence).
Results: Total 50 cases were observed out of which 23 patients belong to group I and 27 patients belong to group II. Ovarian cancer of serous histopathology was commoner than mucinous or other epithelial Ovarian cancer. Preoperative serum CA125 levels were significantly higher for patients with advanced stage II, III, IV(mean286.6, range100-473.2)U/ml compared with patients with stage I(mean128.5, range17-240)U/ml, for patients with serous carcinoma (mean245.1, range17-473.2)U/ml compared with mucinous carcinoma (mean 203, range25-381)U/ml. Preoperative CA 125 level did not predict recurrence.15 cases(30%)had recurrence and all belong to advanced stage Ovarian cancer.